Colorectal Cancer - Shaping the future dynamics of colorectal cancer management

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-10-13

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.


Scope

  • Overview of colorectal cancer including epidemiology forecasts and unmet needs in the disease
  • Clinical and commercial evaluation of key marketed and late-phase pipeline drugs for colorectal cancer
  • Sales forecasts for existing and Phase III developmental drugs for colorectal cancer to 2015 in the seven major markets
  • Key events and factors influencing the sales forecasts for colorectal cancer drugs to 2015 at country level


    • Report Highlights
    Despite remaining the mainstay of colorectal cancer treatment, sales of cytotoxics are expected to be overtaken by those of molecular targeted therapies by 2008, caused by the genericization of Camptosar/Campto and Eloxatin, and the growth of Avastin and Vectibix.

    In spite of strong growth to date, sales of Eloxatin are expected to slow down significantly in the coming years as generic oxaliplatin begins to enter the EU markets. However, continuing growth in the US market means that overall sales of the drug will not decline in the seven major markets until 2013 when the US patent expires.

    There are few drugs currently in Phase III development for colorectal cancer despite the high unmet needs in the disease. Amgen's Vectibix, approved in September 2006 remains the most promising and is likely to overtake Erbitux as the leading monoclonal antibody EGFR inhibitor for colorectal cancer.


    Reasons to Purchase

  • Understand patient segmentation relevant to marketed and pipeline colorectal cancer drugs
  • Assess current and future competitive dynamics of colorectal cancer to determine the future size and scope of the market
  • Identify licensing and lifecycle management opportunities in the colorectal cancer market based on company portfolio and market needs

    • Table of Contents

    Other users found this report page using the following search terms: colorectal cancer cancer colorectal patent expiry vectibix future campto erbitux management drugs

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.